Literature DB >> 15130774

4-Hydroxy tempol-induced impairment of mitochondrial function and augmentation of glucose transport in vascular endothelial and smooth muscle cells.

Evgenia Alpert1, Hamutal Altman, Hanan Totary, Arie Gruzman, Dana Barnea, Varda Barash, Shlomo Sasson.   

Abstract

The water-soluble and cell permeable nitroxide derivative 4-hydroxy tempol (TPL) has been shown to reduce or ameliorate oxidative stress-induced dysfunction and damage in vascular endothelial cells. We studied the effects of TPL on glucose transport and metabolism in bovine aortic endothelial (VEC) and smooth muscle cells (VSMC) under normal and high glucose conditions. Normally, these cells operate an autoregulatory protective mechanism that limits the rate of glucose transport under hyperglycemic conditions by decreasing the cell content of their typical glucose transporter GLUT-1 mRNA and protein as well as its plasma membrane abundance. TPL augmented the rate of glucose transport both under normo- and hyperglycemic conditions by increasing GLUT-1 mRNA and protein content and its plasma membrane abundance in both types of cells, leading to an increased flux of glucose into the cells. These effects were found related to ROS-generating and oxidant activities of TPL and to a decreased rate of mitochondrial ATP production under both normo- and hyperglycemic conditions. Since impaired mitochondrial functions, and in particular decreased rate of ATP production, augment the expression of GLUT-1 protein and glucose transport and metabolism, we suggest that the stimulatory effects of TPL in vascular cells results from its unfavorable interactions in the mitochondrion. It is therefore suggested that effects of TPL in cells of cardiovascular system be evaluated in parallel to its adverse effects on glucose and energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15130774     DOI: 10.1016/j.bcp.2004.02.005

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Design and synthesis of novel protein kinase R (PKR) inhibitors.

Authors:  Sagiv Weintraub; Tali Yarnitzky; Shirin Kahremany; Iliana Barrera; Olga Viskind; Kobi Rosenblum; Masha Y Niv; Arie Gruzman
Journal:  Mol Divers       Date:  2016-08-01       Impact factor: 2.943

2.  Hyperthermia-induced Hsp90·eNOS preserves mitochondrial respiration in hyperglycemic endothelial cells by down-regulating Glut-1 and up-regulating G6PD activity.

Authors:  Tennille Presley; Kaushik Vedam; Lawrence J Druhan; Govindasamy Ilangovan
Journal:  J Biol Chem       Date:  2010-09-22       Impact factor: 5.157

3.  [Effect of the chemoprotectant tempol on anti-tumor activity of cisplatin].

Authors:  Shuangyan Ye; Sisi Zeng; Mengqiu Huang; Jianping Chen; Xi Chen; Pengfei Xu; Qianli Wang; Wenwen Gao; Bingsheng Yang; Bingtao Hao; Wenhuan Huang; Qiuzhen Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-08-30

Review 4.  Effects of tempol and redox-cycling nitroxides in models of oxidative stress.

Authors:  Christopher S Wilcox
Journal:  Pharmacol Ther       Date:  2010-02-11       Impact factor: 12.310

5.  Bilirubin increases the expression of glucose transporter-1 and the rate of glucose uptake in vascular endothelial cells.

Authors:  Guy Cohen; Dan M Livovsky; Jaime Kapitulnik; Shlomo Sasson
Journal:  Rev Diabet Stud       Date:  2006-11-10

6.  Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protective.

Authors:  Sara Morales Palomares; Julie G Sweet; Marilyn J Cipolla
Journal:  Transl Stroke Res       Date:  2012-05-15       Impact factor: 6.829

Review 7.  Chemistry and antihypertensive effects of tempol and other nitroxides.

Authors:  Christopher S Wilcox; Adam Pearlman
Journal:  Pharmacol Rev       Date:  2008-12       Impact factor: 25.468

8.  Tempol, a superoxide dismutase mimetic agent, ameliorates cisplatin-induced nephrotoxicity through alleviation of mitochondrial dysfunction in mice.

Authors:  Lamiaa A Ahmed; Nagwa I Shehata; Noha F Abdelkader; Mahmoud M Khattab
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

Review 9.  Are Antioxidants a Potential Therapy for FSHD? A Review of the Literature.

Authors:  Adam Philip Denny; Alison Kay Heather
Journal:  Oxid Med Cell Longev       Date:  2017-06-12       Impact factor: 6.543

10.  The heterocyclic compound Tempol inhibits the growth of cancer cells by interfering with glutamine metabolism.

Authors:  Shuangyan Ye; Pengfei Xu; Mengqiu Huang; Xi Chen; Sisi Zeng; Qianli Wang; Jianping Chen; Keyi Li; Wenwen Gao; Ruiyuan Liu; Jingxian Liu; Yihao Shao; Hui Zhang; Yang Xu; Qianbing Zhang; Zhuo Zhong; Zibo Wei; Jiale Wang; Bingtao Hao; Wenhua Huang; Qiuzhen Liu
Journal:  Cell Death Dis       Date:  2020-05-04       Impact factor: 9.685

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.